Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oncotelic Therapeuti (OTLC)
0.2349 ? -0.0101 (-4.12%)
Volume: 66,900 @03/11/22 3:45:05 PM EST
Bid Ask Day's Range
0.1998 0.24 0.22725 - 0.2495
OTLC Detailed Quote
Oncotelic to Present New Studies on its TGF-ß Program at the American Association for Cancer Research (AACR) Annual Meeting 2022: https://apnews.com/press-release/globe-newswire/covid-science-health-business-clinical-trials-c5034ebe6c6a0b3af63824de15a23acf
Questions: I did some DD and was excited about the Pulmo Heal product, but found what I think are two things I could not be 100% sure about:
1. is that it seems Pulmo Heal is a being sold without a prescription in the US, but the 10Q calls it a drug at some point... I don't think it is a prescription or will require a prescription. So this means it will compete against other dietary supplements...
2. Another report suggested that the quality and saftey index for Pulmo Heal is superior, but without more information I found it hard to tell if there version of artemisinin was actually or significantly better than other products being sold by other companies. Any thoughts or info on these.
This is my research
Oncotelic; An Introduction to CFO Amit Shah & His Industry Background:
Oncotelic; An Introduction to CBO GM of AI Division Saran Saund and His Background:
Oncotelic; An Introduction to Chief Clinical Officer Anthony Maida & His Background:
Oncotelic Therapeuti (OTLC)
0.165 ? -0.005 (-2.94%)
Volume: 112,628 @02/04/22 1:36:43 PM EST
Bid Ask Day's Range
0.16 0.165 0.1511 - 0.165
OTLC Detailed Quote
Oncotelic Presenting at BiotechGate Digital Partnering: https://finance.yahoo.com/news/oncotelic-presenting-biotechgate-digital-partnering-140500384.html
$OTLC Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
Thinking the same..chart has been on the climb.. .20 break gets more eyes t think..
wouldn't be surprised if it was a fake wall to scare up some selling
$OTLC .19 up with a wall..watching for a break higher if it falls…
looks like we've got the loading block at .19 up next
$OTLC bidders at .18 now..continues to gain strength..
agreed, just need that dumb seller at .19 to move or split up his order
Yeah a lot of the OTC is pretty slow today.
Quiet trading day..chart still holding strong..
$OTLC Low Float play, moves on air..
I don't see any resistance at all on the chart. This is about to open up very nicely in my opinion.
$OTLC next leg up on the chart starting, if we can break .188 (200 DMA) today then we could be looking at a blue sky breakout https://schrts.co/cgsKYpbQ
$OTLC Trading very well here..cross the 200 day ma at .188 and I think this really picks up steam..
https://stockcharts.com/c-sc/sc?s=OTLC&p=D&b=5&g=0&i=0&r=1641553280057
$OLTC impressed with today..as .17 broke through and now strong support at .176..
Why 2022 Could Open Gangbusters for Covid Stocks (AZN, OTLC, NVAX, PFE, MRNA, MRK, JNJ, BNTX)
Oncotelic Therapeutics Inc (OTC:OTLC) bills itself as an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. The Covid-19 story here is also compelling.
OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19, with data cleaning and evaluation and datalock ongoing.
Oncotelic Therapeutics Inc (OTC:OTLC) most recently announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (ORF8) is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients.
Fatality in hospital patients is associated with higher serum levels of ORF8. ORF8 is one of the least well conserved and most variable parts of the SARS-CoV-2 genome.
“It is gratifying to identify what we think is the fundamental evolutionary pathway for SARS-CoV-2,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.”
OTLC shares are up over 60% in the past six weeks, leading the Covid stock space. The stock is also cheap, trading at just $0.16/share, but with upward trending technical dynamics, including its recent breakout above its 50-day moving average.
Oncotelic Therapeutics Inc (OTC:OTLC) noted in its release that it has identified 30 high entropy amino acid residues which underwent a progressive evolution to arrive at the current dominant variant – Delta variant. The virus underwent mutational waves, with the first wave made up of structural proteins important in its infectivity, and the second wave made up of the ORFs important for its contagion. The most important driver of the second wave is ORF8 mutations at residue 119 and 120. Further mutations of these two residues are creating new lineage trees that are offshoots from the Delta backbone. More importantly the further mutational expansion of the S-protein in the emerging Omicron variant is now followed with the acquisition of ORF8 mutations 119 and 120.
Novavax Inc. (NASDAQ:NVAX) focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.
The stock has become a johnny-come-lately potential star for speculators in principle if not in fact as the allure of its more simple, easier to store, easier to manufacture, easier to transport, more traditional yet still effective vaccine solution has been widely touted as a potential long-term winner because it translates better to emerging markets around the world, where new variants are thought to be incubating.
https://www.benzinga.com/pressreleases/22/01/ab24866863/why-2022-could-open-gangbusters-for-covid-stocks-azn-otlc-nvax-pfe-mrna-mrk-jnj-bntx
$OTLC Breakout is imminent imo..
$OTLC looks ready for the next leg up on this bull flag chart https://schrts.co/GCBCKMRy
$OTLC got my eyes on these bidders..keep moving up…
business is picking up here! .185's almost gone then we get to test out that loading wall at .19
$OTLC Volume picking up..looks like we finally see that .20 test….
$OTLC Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-ß therapeutics for oncology and virology, today announced that it has submitted a clinical study protocol to the United States Food and Drug Administration (“US FDA”) for the initiation of a Phase 1 Clinical Trial for CA4P, the Company’s Vascular Disrupting Agent, in combination with Anti-PD-1 (pembrolizumab) as a treatment for patients with Melanoma.
The Phase 1 Clinical Trial is designated as S101: Phase 1, Prospective, Multicenter, Open-Label, Single Arm Study of Safety and Initial Efficacy of CA4P in Combination with anti-PD1 (pembrolizumab) in Patients with Recurrent Metastatic Cutaneous or Uveal Melanoma.
CA4P has been evaluated in over 500 patients and treated in 17 clinical studies to date. These included multiple Phase 1 dose escalation studies, with dose cohorts up to 114 mg/m2, when used as monotherapy, 63 mg/m2 when used in combination with paclitaxel, and 63 mg/m2 when used in combination with bevacizumab. Based on the early Phase 1 studies, CA4P was further studied in larger Phase 2 studies including:
• Ovarian cancer - 60 mg/m2 CA4P in combination with 15 mg/kg bevacizumab (n=54) in combination with physician’s choice chemotherapy;
• Anaplastic thyroid cancer - 60 mg/m2 CA4P in combination with paclitaxel and carboplatin q3wk (n=51);
• Platinum resistant ovarian cancer - 63 mg/m2 CA4P in combination with paclitaxel and carboplatin q3wk (n=44);
• Non-small cell lung cancer - 60 mg/m2 CA4P in combination with bevacizumab and with paclitaxel and carboplatin q3wk (n=31).
CA4P was generally well tolerated in these studies, and toxicity did not appear to be significantly related to dose frequency. The Company believes that the combination of CA4P together with checkpoint inhibitors, such as pembrolizumab, could be synergistic. Mechanistically, the trial is also designed to assess the impact of CA4P on tumoral TGF-ß signature which would allow us to integrate CA4P into our TGF-ß platform as combination with checkpoint inhibitors, CAR-T, and vaccine/oncolytic viruses.
“This is the first of a series of planned clinical trials in melanoma patients to ultimately obtain marketing approval for CA4P in a Rare Pediatric Disease. The US FDA has previously granted the Company a Rare Pediatric Disease Designation for CA4P/ Fosbretabulin for the treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients.” noted Dr. Vuong Trieu, Chairman and Chief Executive Office of Oncotelic.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.
Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. in November 2019.
For more information, please visit www.oncotelic.com
https://finance.yahoo.com/news/oncotelic-initiates-phase-1-trial-130100307.html
nice to see this pop over .18 today - that's a key level to break and hold on the daily chart IMO
Looks like it's trying to form a cup and handle on the chart. Probably see .20 break today in my opinion.
$OTLC strong start here! Bidders moved up over previous resistance! Looks like it’s go time!
Definitely a steal at this price. Almost criminal.
Absolutely..looking forward to what they are bringing to the table..
this stock reminds me of some nasdaq biotechs I've traded, yet this one is on the OTC at only.17
that's usually how these biotechs operate, don't want to be presenting at a conference without some powerful updates
Thinking we might see an update leading in to the conference…
Two drugs going through clinical trials. One for mesothelioma and one for melanoma. Very impressive for a small and fairly unknown penny stock. If either one of these is successful then you're talking potential buyout candidate by a big pharmaceutical in my opinion. Most new drugs don't even make it into phase 1 studies. The preliminary efficacy studies kill a lot of the drugs before they reach phase 1.
news looked good, they have lot of simultaneous testing going on at the same time on covid and cancer drugs - huge potential if anyone of them proves effective
Love this from the news yesterday…
The Phase 1 Clinical Trial is designated as S101: Phase 1, Prospective, Multicenter, Open-Label, Single Arm Study of Safety and Initial Efficacy of CA4P in Combination with anti-PD1 (pembrolizumab) in Patients with Recurrent Metastatic Cutaneous or Uveal Melanoma.
CA4P has been evaluated in over 500 patients and treated in 17 clinical studies to date. These included multiple Phase 1 dose escalation studies, with dose cohorts up to 114 mg/m2, when used as monotherapy, 63 mg/m2 when used in combination with paclitaxel, and 63 mg/m2 when used in combination with bevacizumab. Based on the early Phase 1 studies, CA4P was further studied in larger Phase 2 studies including:
• Ovarian cancer - 60 mg/m2 CA4P in combination with 15 mg/kg bevacizumab (n=54) in combination with physician’s choice chemotherapy;
• Anaplastic thyroid cancer - 60 mg/m2 CA4P in combination with paclitaxel and carboplatin q3wk (n=51);
• Platinum resistant ovarian cancer - 63 mg/m2 CA4P in combination with paclitaxel and carboplatin q3wk (n=44);
• Non-small cell lung cancer - 60 mg/m2 CA4P in combination with bevacizumab and with paclitaxel and carboplatin q3wk (n=31).
$OTLC Really wants that .20 test here!
For being a light volume day it's trading very well. Currently sitting at about 1/3 of the average 10-day but I think this will have a nice run into close today.
$OTLC looks like it wants to POP soon!
big conference presentation Jan 25-27 for OTLC, there is usually big news released ahead of these types of things - something to keep an eye on
https://www.otcmarkets.com/stock/OTLC/news/Oncotelics-Dr-Anthony-Maida-to-Present-at-2nd-Annual-TGF--for-Immuno-Oncology-Drug-Development-Summit-in-January-2022?id=335678
spread just closed up, looking thin for a push over .18
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
956
|
Created
|
08/23/16
|
Type
|
Free
|
Moderators |
Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs.
We have a history of successful partnerships and welcome new collaboration and licensing opportunities.
Interested parties may contact:
Chulho Park PhD, Chief Technology Officer
Oncotelic Inc.
29397 Agoura Rd., Suite 107
Agoura Hills, CA 91301
bd@oncotelic.com
(650) 635-7000
Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by
Cancer Research UK (CRUK) along with additional academic partners.
Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust
and coordinated by the Manchester Academic Health Science Centre,
Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust,
and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).
This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib
alone for the treatment of advanced recurrent ovarian cancer.
We are providing CA4P for use in this trial.
Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297).
The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors.
In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of
CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.
The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data.
Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable
vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide.
We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQB Market under the symbol “MATN”.
We are headquartered in Agoura Hills, California
https://www.oncotelic.com/pointr-data/
EdgePoint AI was established in order to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning
models at a fraction of the power and budget of mainstream computing in pharmaceutical manufacturing.
The company’s technology solution “TrustPoint” provides an AI computing platform for pharmaceutical and healthcare verticals
including blockchain support for manufacturing where data integrity and security are of utmost importance.
EdgePoint is composed of a team of executives with pharmaceutical drug development, GMP manufacturing and deep AI knowledge.
The team includes Steven King who was the former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned
contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its
lead compound through Phase 3 development, while growing revenues to over $55 million;
Seasoned executive, Saran Saund who has been founder, CEO and GM at several startups and public companies for which he returned
significant value to shareholders in his startups and chief technology officer; Burcak Beser who has been founder and
CTO of several successful private and public companies with over 144 patents during his career; and Lisa Stepp with broad experience in
executive leadership across geographies and in all aspects of drug development and program management.
The core technology platform for EdgePoint AI came from PointR -which was acquired by Mateon in Nov 2019. Examples of PointR capabilities are shown below.
http://oncotelic.com/wp-content/uploads/LosAngelesBusinessJournal2018-05-21.pdf
Health Care: Drug Developer Adds Digital Monitor
TWO YEAR CHART: NASDAQ
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |